CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2017--
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical
oncology company advancing novel product candidates based on its
Targeted Protein Therapeutics (TPTs) platform, today announced that Dr.
Gregory Adams, Chief Scientific Officer, will chair a session focused on
antibody drug conjugates and fusion proteins at the Antibody Engineering
and Therapeutics Meeting in San Diego, CA. As part of the session, Dr.
Adams will give a talk on the potential for tumor-targeted payloads to
prime the immune system to facilitate more effective therapy in
combination with immuno-oncology agents, including checkpoint inhibitors.
“Checkpoint inhibitors are a significant step forward in the quest to
engage the patient’s immune system in the fight against cancer.
Checkpoint inhibitors function by blocking the signals that cancers use
to inhibit the immune system. However, for checkpoint inhibitors to be
effective, they require the presence of an active immune response
against the cancer. There is broad recognition of the potential for
tumor-targeted payloads, such as Eleven’s Targeted Protein Therapeutics
(TPTs), to provide this spark to the immune system and act
synergistically with checkpoint inhibitors,” said Dr. Gregory Adams,
Chief Scientific Officer of Eleven Biotherapeutics. “Earlier this year
at the American Association of Cancer Research Conference, we presented
data which supports this potential, demonstrating that TPTs induce
immunogenic cell death as evidenced by the presence of damage-associated
molecular patterns. Our collaboration with the National Cancer Institute
and AstraZeneca aims to build on this evidence.”
Title: Antibody-Drug Conjugates & Fusion
Date: Wednesday, December 13,
Time: 8:10 am - 12:00 pm PT
Manchester Grand Hyatt; San Diego, CA
Vicinium™ is manufactured as a single protein anti-epithelial cell
adhesion molecule (anti-EpCAM) fusion protein fused with Pseudomonas
Exotoxin A (ETA) designed to specifically target and deliver a potent
anti-cancer payload directly into tumor cells. It is constructed with a
stable, genetically-engineered linker to ensure its potent protein
payload remains attached until it is internalized by the cancer cell,
which is believed to decrease the risk of toxicity to healthy tissues
thereby improving the compound’s safety. Vicinium’s™ one-step
manufacturing process offers significant cost advantages and results in
the production of a homogenous product, with less batch-to-batch
variability than most antibody drug conjugates. Vicinium™ is currently
in a Phase 3 registration clinical trial for the treatment of high-grade
non-muscle invasive bladder cancer (NMIBC) in patients who have
previously received two courses of Bacillus Calmette-Guérin (BCG) and
whose disease is now BCG-unresponsive. Eleven Biotherapeutics intends to
enroll 134 subjects in the trial, including 77 subjects with carcinoma
in situ (CIS), at over 70 centers in the United States and Canada.
Primary and secondary endpoints include complete response (CR) in CIS
subjects, time to disease recurrence and event free survival. The
Company expects to complete patient enrollment in the first quarter of
2018 and to report topline three-month data in mid-2018.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology company
advancing novel product candidates based upon the Company’s targeted
protein therapeutics (TPTs) platform. TPTs incorporate a tumor-targeting
antibody fragment and a protein cytotoxic payload into a single protein
molecule in order to achieve focused tumor cell killing. Eleven’s lead
TPT, Vicinium™, is currently in a Phase 3 trial in non-muscle invasive
bladder cancer, with topline three-month data expected in mid-2018. The
Company believes its TPT approach offers significant advantages in
treating cancer over existing antibody drug conjugate technologies. The
Company believes its TPTs provide effective tumor targeting with broader
cancer cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistant mechanisms. Additionally, the Company believes that its TPT’s
cancer cell-killing properties promote an anti-tumor immune response
that will potentially combine well with immune oncology drugs such as
checkpoint inhibitors. For more information, please refer to the
Company’s website at www.elevenbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213005348/en/
Source: Eleven Biotherapeutics, Inc.
Stern Investor Relations, Inc.
Michael Schaffzin, 212-362-1200